1921
Volume 87, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy. Each treatment consisted of one to four intralesional applications of MA at 15-day intervals. Patients' age ranged from 3 to 90 years; fourteen were females. Intralesional treatment in the absence of any relevant toxicity was successful in 20 (83.3%) patients. Three patients required additional treatment with amphotericin B and one required systemic MA. None of the patients developed mucosal lesions when followed up to 60 months. Intralesional MA is an effective and less toxic alternative treatment of patients with CL and contraindication to systemic therapy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.11-0612
2012-08-01
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/87/2/257.html?itemId=/content/journals/10.4269/ajtmh.2012.11-0612&mimeType=html&fmt=ahah

References

  1. Ministério da Saúde Saúde SdVe, 2010. Manual de Vigilância da Leishmaniose Tegumentar Americana. , ed: Editora MS, 78.
  2. Goodwin LG, , 1995. Pentostan (sodium stibogluconate); a 50-year personal reminiscence. Trans R Soc Trop Med Hyg 89: 339341.[Crossref]
  3. Herwaldt BL, , 1999. Leishmaniasis. Lancet 354: 11911199.[Crossref]
  4. Andersen EMC-SM, Llanos-Cuentos A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, , 2005. Comparison of meglumine antimoniate and pentamidine for perureian cutaneous leishmaniasis. J Trop Med Hyg 72: 133137.
  5. Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA, Jr Magill AJ, Endy TP, Coyne PE, Grogl M, Benson PM, Beard JS, Tally JD, Gambel JM, Kreutzer RD, Oster CN, , 1998. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 27: 14571464.[Crossref]
  6. Ribeiro AL, Drummond JB, Volpini AC, Andrade AC, Passos VM, , 1999. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 32: 297301.[Crossref]
  7. DAIDS, 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events: DAIDS Regulatory Support Center.
  8. Romero GA, Mendonça S, Schubach A, Noronha E, Matos M, Dietze R, , 2006. O desafio para a realização de ensaios clínicos em leishmaniose tegumentar. Revista da Sociedade Brasileira de Medicina Tropical 39 (III Suppl): 100103.
  9. Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Araújo ML, Francesconi-do-Vale AC, Passos SRL, Marzochi MC, , 2005. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc Bras Med Trop 38: 213217.[Crossref]
  10. Marsden P, Llanos Cuentas E, Lago E, Cuba C, Barreto A, Costa J, Jones T, , 1984. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia - Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Bras Med Trop 17: 179186.[Crossref]
  11. Ampuero J, , 2009. Efficacy and safety of low-dose pentavalent antimonial for treatment of cutaneous leishmaniasis by Leishmania (Viannia) braziliensis in Bahia, Brazil: a randomized clinical trial. Thesis, Núcleo de Medicina Tropical. Brasília - DF: Universidade de Brasília, 260.
  12. Schubach A, Marzochi MC, Cuzzi-Maya T, Oliveira AV, Araújo ML, Oliveira AL, Pacheco RS, Momen H, Conceição-Silva F, Coutinho SG, Marzochi KB, , 1998. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 58: 824827.
  13. de Paula CDSJ, Cardoso DR, Sampaio RN, , 2003. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 36: 365371.[Crossref]
  14. Saldanha AC, Romero GA, Guerra C, Merchan-Hamann E, Macedo VO, , 2000. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Rev Soc Bras Med Trop 33: 383388.[Crossref]
  15. Soto J, Buffet P, Grogl M, Berman J, , 1994. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 50: 107111.
  16. de Camargo Ferreira EV, de Oliveira Schubach A, Valete-Rosalino CM, de Souza Coutinho R, Conceicao-Silva F, de Matos Salgueiro M, Rosandiski Lyra M, Soares Moreira J, Azeredo-Coutinho RB, Fernandes Pimentel MI, Roberto Mortari S, de Fatima Madeira M, Pereira Quintella L, Baptista C, de Almeida Marzochi MC, , 2010. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. J Am Geriatr Soc 58: 614616.[Crossref]
  17. Claros P, Wienberg P, Gonzalez MA, Claros A, Claveria MA, Lopez P, , 1996. Intralesional treatment of cutaneous leishmaniasis: a report of two cases. Acta Otorrinolaringol Esp 47: 6770.
  18. Harms G, Chehade AK, Douba M, Roepke M, Mouakeh A, Rosenkaimer F, Bienzle U, , 1991. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 85: 214216.[Crossref]
  19. Sharquie KEA-TK, Chu AC, , 1988. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 119: 5357.[Crossref]
  20. Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Jamal A, , 1996. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 35: 594597.[Crossref]
  21. Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi G, Jr Fernandes O, , 1998. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 178: 911914.[Crossref]
  22. Mendonça MG, De Brito ME, Rodrigues EH, Bandeira V, Jardim ML, Abath FG, , 2004. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 189: 10181023.[Crossref]
  23. Schubach A, Cuzzi-Maya T, Oliveira AV, Sartori A, de Oliveira-Neto MP, Mattos MS, Araujo ML, Souza WJ, Haddad F, Perez Mde A, Pacheco RS, Momen H, Coutinho SG, de Almeida Marzochi MC, Marzochi KB, da Costa SC, , 2001. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem Inst Oswaldo Cruz 96: 987996.[Crossref]
  24. Wortmann GW, Miller RS, Blazes D, Oster CN, , 2000. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 31: 199201.[Crossref]
  25. Marsden PD, Tada MS, Barreto AC, Cuba CC, , 1984. Spontaneous healing of Leishmania braziliensis braziliensis skin ulcers. Trans R Soc Trop Med Hyg 78: 561562.[Crossref]
  26. Zajtchuk JT, Netto EM, Grogl M, Neafie RC, Hessel CR, de Magalhaes AV, Marsden PD, , 1989. Mucosal leishmaniasis in Brazil. Laryngoscope 99: 925939.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.11-0612
Loading
/content/journals/10.4269/ajtmh.2012.11-0612
Loading

Data & Media loading...

  • Received : 04 Oct 2011
  • Accepted : 18 Apr 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error